Design Therapeutics, Inc. filed a Form S-3 shelf registration statement with the U.S. Securities and Exchange Commission on November 4, 2026, covering the potential offering of up to $300,000,000 in securities.

Key Highlights

  • Shelf size: The registration covers up to $300,000,000 of securities in the aggregate.
  • Security types: The filing registers common stock, preferred stock, debt securities, and warrants, in any combination.
  • Stock price at filing: The last reported sale price of common stock on November 3, 2026 was $10.34 per share, according to the filing.
  • Listing: Common stock trades on The Nasdaq Global Select Market under the symbol "DSGN."
  • Company classification: Design Therapeutics is identified in the filing as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
  • Offering structure: Sales may occur from time to time directly to investors, through agents, or through underwriters or dealers, with specific terms to be set in prospectus supplements.

Design Therapeutics Registers Up to $300 Million in Mixed Securities via Shelf Process

Design Therapeutics, Inc. (NASDAQ:DSGN), based in Carlsbad, California, filed a Form S-3 registration statement on November 4, 2026, initiating a shelf registration process under which the company may offer and sell up to $300,000,000 of securities over time. The registrant's principal executive offices are located at 6005 Hidden Valley Road, Suite 110, Carlsbad, California 92011, and its agent for service is Pratik Shah, Ph.D., President, Chief Executive Officer and Chairperson.

According to the filing, the shelf covers any combination of common stock, preferred stock, debt securities, and warrants to purchase any such securities. The company disclosed that it may also offer securities issuable upon conversion, redemption, repurchase, exchange, or exercise of any registered securities, including pursuant to applicable antidilution provisions. The filing notes that this prospectus "may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement," meaning specific terms of any individual offering will be detailed separately at the time of that offering.

The filing states that the company has elected not to use the extended transition period for complying with new or revised financial accounting standards, as permitted for emerging growth companies under Section 7(a)(2)(B) of the Securities Act. The registration statement was filed under Rule 415, which permits offerings on a delayed or continuous basis. The filing cautions that investing in the company's securities involves "a high degree of risk" and directs prospective investors to the Risk Factors section on page 5 of the prospectus.

What Was Disclosed

Design Therapeutics filed a shelf registration statement on November 4, 2026, registering up to $300,000,000 in common stock, preferred stock, debt securities, and warrants. No specific offering has been launched; each future offering will be described in a separate prospectus supplement.